Ibuprofen Patent Expiration
Ibuprofen was first introduced by Mcneil Consumer Healthcare Div Mcneil Ppc Inc
Ibuprofen Patents
Given below is the list of patents protecting Ibuprofen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Caldolor | US11806400 | Injectable ibuprofen formulation | Mar 16, 2032 | Apotex |
| Caldolor | US9072661 | Injectable ibuprofen formulation | Mar 16, 2032 | Apotex |
| Caldolor | US9072710 | Injectable ibuprofen formulation | Mar 16, 2032 | Apotex |
| Caldolor | US9012508 | Administration of intravenous ibuprofen | Sep 14, 2030 | Apotex |
| Caldolor | US8735452 | Treating patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Caldolor | US8871810 | Treating critically ill patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Caldolor | US9114068 | Treating patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Caldolor | US9138404 | Treating critically ill patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Caldolor | US9295639 | Treating critically ill patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Caldolor | US9649284 | Treating critically ill patients with intravenous ibuprofen | Sep 30, 2029 | Apotex |
| Children's Advil-flavored | US10238640 | Pharmaceutical suspension composition |
May 25, 2024
(Expired) | Haleon Us Holdings |
| Caldolor | US6727286 | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
Nov 27, 2021
(Expired) | Apotex |
| Midol Liquid Gels | US6251426 | Ibuprofen-containing softgels |
Jun 25, 2018
(Expired) | Bionpharma |
Ibuprofen's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ibuprofen:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
